In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Intersect ENT, Inc.. Trade Record

NASDAQ:XENT Intersect ENT, Inc. stock gains 9.16% Exit Mar 4, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart XENT Feb 11, 2019, priceSeries
About Intersect ENT, Inc.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
94.67
Entry Date
Feb 11, 2019
Entry Price
30.53
Sell Date
Mar 4, 2019
Sell Price
33.33
Net Gain
9.16%
Hold Time
14 Trading Days